NCT02306954 2025-03-10
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
Phase 2 Active not recruiting
Clinical Trials
16 trialsNCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT03501381 2023-09-01
High Dose IL 2 and Entinostat in RCC
Hoosier Cancer Research Network
Phase 2 Active not recruiting
NCT00325507 2020-10-19
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
Oxford BioMedica
Phase 2 Completed
NCT00582790 2019-11-25
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT03226236 2018-11-13
RENALVax-2
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Withdrawn
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00440973 2016-03-17
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00913913 2015-12-01
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT01274273 2014-12-02
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
University of Aarhus
Phase 2 Unknown
NCT00203866 2013-09-05
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
University of Chicago
Phase 2 Terminated
NCT00031564 2012-09-27
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00485563 2012-03-08
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Endocyte
Phase 2 Terminated
NCT00393029 2011-08-15
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01176552 2010-08-24
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Kidney Cancer Research Bureau
Phase 2 Completed
NCT00609401 2009-02-26
ROSORC
Italian Trial in Medical Oncology
Phase 2 Completed